Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Macdonald, DA
  • Assouline, SE
  • Brandwein, J
  • Kamel-Reid, S
  • Eisenhauer, EA
  • Couban, S
  • Foo, A
  • Leber, Brian

publication date

  • May 20, 2010